Kadem Arslan* and Suleyman Bas

Department of Internal Medicine, Sancaktepe Martyr Prof. Dr. Ilhan Varank Training and Research Hospital, Istanbul, Turkey

*Corresponding Author: Kadem Arslan, Department of Internal Medicine, Sancaktepe Martyr Prof. Dr. Ilhan Varank Training and Research Hospital, Istanbul, Turkey.

Received: October 26, 2021; Published: November 23, 2021

Abstract

Aims: We aimed to determine the frequency of troponin elevations in COVID-19 patients and to investigate the role of troponin in demonstrating the prognosis of COVID-19 by examining the clinical course of theese patients.

Methods: Patients diagnosed with COVID-19 disease were included in the study. Patient files were analyzed retrospectively through the hospital information management system. Patients with high troponin levels were identified and comparisons were made with patients with normal troponin levels.

Results: 1468 patients were included in the study.Troponin level was found to be high in 6.7% of the patients.The presence of pneumonia on thorax CT rate,hospitalization rate,ICU admission rate,intubation rate was significantly higher in patients with high troponin levels.The mortality rate was 2.1% in the whole group.The mortality rate was significantly higher in the patients with high troponin levels.Total length of hospital and ICU stay were significantly higher in patients with high troponin levels.There was a significant positive correlation between the troponin levels of the patients at admission and the total length of hospital stay and length of ICU stay. 49.5% of COVID-19 patients had another comorbid disease.Hypertension was the most common comorbid disease. The rate of troponin elevation and troponin levels were significantly higher in patients with other comorbid diseases.

Conclusion: It has been found that high troponin levels in COVID-19 patients may be associated with a poor clinical prognosis. Troponin can be used as a predictor of prognosis with more comprehensive studies and long-term follw-up results in the future.

Keywords: COVID-19; SARS-CoV-2; Troponin; Cardiac Biomarkers; Prognosis

References

1. Alpert JS., et al. “Myocardial infarction redefined-a consensus document of the Joint European ociety of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction”. Journal of the American College of Cardiology 36 (2000): 959-969.
2. Roffi M., et al. “2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation”. Task Force for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation of the European Society of Cardiology (ESC). European Heart Journal 37 (2016): 267-315.
3. Alcalai R., et al. “Acute coronary syndrome vs nonspecific troponin elevation: clinical predictors and survival analysis”. Archives of Internal Medicine 167 (2007): 276-281.
4. Wong JA., et al. Canadian Acute Coronary Syndromes I and II, and Canadian Global Registry of Acute Coronary Events (GRACE/GRACE) Investigators. “Temporal management patterns and outcomes of non‐ST elevation acute coronary syndromes in patients with kidney dysfunction”. European Heart Journal 30 (2009): 549-557.
5. Rothan HA and Byrareddy SN. “The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak”. Journal of Autoimmunity 109 (2020): 102433.
6. Lai CC., et al. “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges”. International Journal of Antimicrobial Agents3 (2020): 105924.
7. Poutanen SM. “Etiologic agents of infectious diseases”. In: Long SS, editor. Principles and practice of paediatric infectious diseases. 4th ed (2012): 1547-712.
8. Pal M., et al. “Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update”. Cureus3 (2020): e7423.
9. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 497-506.
10. Zhang H., et al. “Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target”. Intensive Care Medicine 46 (2020): 586-590.
11. Hamming I., et al. “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis”. The Journal of Pathology2 (2004): 631-637.
12. Alhogbani T. “Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus”. Annals of Saudi Medicine 36 (2016): 78-80.
13. Oudit GY., et al. “SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS”. European Journal of Clinical Investigation 39 (2009): 618-625.
14. Shi S., et al. “Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China”. JAMA Cardiology (2020): e200950.
15. Piccioni A., et al. “Role of troponin in COVID-19 pandemic: a review of literature”. European Review for Medical and Pharmacological Sciences19 (2020): 10293-10300.

Citation

Citation: Kadem Arslan and Suleyman Bas. “Frequency of Troponin Elevations in Patients with Covıd-19 and Clinical Course in these Patients”. Acta Scientific Gastrointestinal Disorders 4.12 (2021): 26-33.

Copyright

Copyright: © 2021 Kadem Arslan and Suleyman Bas. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.